Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Fundacion Grupo Espanol De Investigacion En Cancer De Mama is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Sponsor Greenwich LifeSciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Sponsor NSABP Foundation Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Approximately 29% of screened patients (638/2,188) were screening failures.
- Slow enrollment prompted an amendment to revise statistical planning.
- Consistently low monthly EFS event rates in 2024 led to amendment of the analysis plan to permit definitive analysis at 242 rather than 252 confirmed EFS events.
- Following FDA approval of pembrolizumab for high-risk early-stage triple-negative breast cancer, 29 US patients discontinued neoadjuvant protocol therapy to initiate pembrolizumab without being counted as EFS events.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Sponsor Artios Pharma Limited
- Start (EU)
- Latest update
- Estimated end
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
Sponsor Fondazione Michelangelo
- Start (EU)
- Not reported
- Latest update
- Estimated end
CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)
Sponsor Torl Biotherapeutics LLC
- Start (EU)
- Latest update
- Estimated end
A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer “TRIFOUR study”
Sponsor Cantargia AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Fundacion Grupo Espanol De Investigacion En Cancer De Mama?
The 2026-10-09 snapshot links Fundacion Grupo Espanol De Investigacion En Cancer De Mama to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Investigator recruitment, Regulatory services, among 15 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fundacion Grupo Espanol De Investigacion En Cancer De Mama?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fundacion Grupo Espanol De Investigacion En Cancer De Mama conducted?
The linked trials record locations in 17 countries, including Spain, Germany, Austria, Belgium, France. These are trial locations, not confirmed office locations or countries where Fundacion Grupo Espanol De Investigacion En Cancer De Mama delivered services.
What can this page tell me about Fundacion Grupo Espanol De Investigacion En Cancer De Mama's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Fundacion Grupo Espanol De Investigacion En Cancer De Mama. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Fundacion Grupo Espanol De Investigacion En Cancer De Mama